Generic
Dabigatran
Brand Name
Pradaxa
Import ID
121
Dabigatran
| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Lenacapavir Dabigatran | Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potential increased risk of bleeding |
Use with caution. Monitor for dabigatran adverse effects (e.g. bleeding) |
|||
| Ritonavir Dabigatran 1059 | Green: Administer standard doses | Administer standard doses | Potential for increased risk of bleeding |
Not studied |
Not studied (may increase dabigatran levels) |
No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min. |
|
| Darunavir Dabigatran 963 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: risks likely to outweigh benefits | Potential for increased bleeding risk |
Avoid combination and use alternative anticoagulant |
|||
| Darunavir Dabigatran 900 | Green: Administer standard doses | Administer standard doses | No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min. |
||||
| Atazanavir Dabigatran 809 | Green: Administer standard doses | Administer standard doses | Potential for increased risk of bleeding |
No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min. |
|||
| Atazanavir Dabigatran 808 | Green: Administer standard doses | Administer standard doses | Potential for increased risk of bleeding |
No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min. |
|||
| Elvitegravir Dabigatran 236 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potential for increased risk of bleeding |
Dosing depends on indication and renal function. For DVT and PE, avoid co-administration if CrCL < 50 mL / min. For stroke and embolism prevention in persons with atrial fibrillation, do not coadminister in severe renal insufficiency (CrCL< 30mL / min) and consider dose reduction to 75 mg twice daily if CrCL between 30 - 50mL / min |
